Oramed Pharmaceuticals (NASDAQ:ORMP) Given Media Sentiment Score of 0.20
News stories about Oramed Pharmaceuticals (NASDAQ:ORMP) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oramed Pharmaceuticals earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.2179076244921 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Oramed Pharmaceuticals (NASDAQ ORMP) traded up 0.25% during trading on Monday, reaching $8.06. The company’s stock had a trading volume of 33,716 shares. The company has a 50 day moving average price of $8.01 and a 200-day moving average price of $7.14. The company’s market capitalization is $107.36 million. Oramed Pharmaceuticals has a 52 week low of $5.70 and a 52 week high of $9.17.
Separately, HC Wainwright set a $25.00 price objective on Oramed Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, May 22nd.
In related news, Director Xiaopeng Li purchased 89,636 shares of the company’s stock in a transaction on Wednesday, August 2nd. The stock was bought at an average price of $8.50 per share, with a total value of $761,906.00. Following the completion of the transaction, the director now owns 206,350 shares of the company’s stock, valued at approximately $1,753,975. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 27.50% of the company’s stock.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Receive News & Stock Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.